Clinical TrialID 7305
Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection
NCT05504057
COVID-19
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 7305
- Evidence Id
- 7305
- Core Evidence Id
- 7305
- Source Clinical Trial Id
- 7295
- Herb2 Clinical Trial Id
- HBCT007295
- Nct Id
- NCT05504057
- Title
- Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection
- Status
- Recruiting
- Phase
- Study Result
- No
- Study Condition
- COVID-19
- Study Type
- Observational
- Study Design
- Observational Model: |Time Perspective: p
- Intervention
- DRUG: Antihistamine|DRUG: Amantadine
- Intervention Allocation
- Intervention Model
- Intervention Mask
- Intervention Purpose
- Gender
- All
- Age
- Child, Adult, Older_Adult
- Enrollment
- 170000
- Outcome Measure
- Hospital Admissions., Rate of Hospitalization among COVID 19 infections, from march 2020.
- Sponsor Collaborator
- Consorci Sanitari de Terrassa|Institut Català de la Salut
- Funded By
- OTHER
- Location
- Hospital de Terrassa, Terrassa, Barcelona, 08227, Spain|Hospital of Terrassa, Terrassa, Barcelona, 08227, Spain
- Other Id
- 02-22-161-060
- Start Date
- 2020-03-01
- Primary Completion Date
- 2024-09-30
- Completion Date
- 2025-06-13
- First Posted
- 2022-08-17
- Results First Posted
- Last Update Posted
- 2024-04-26
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT05504057
- Title Cn
- Title En
- Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection
- Bilingual Status
- semi_complete